What if the secret to truly personalized precision medicine lies not in your genetic code, but in your zip code?
For years, biotech has focused on genomics to explain disease and drug response, but DNA only accounts for a fraction of the story. The real breakthrough? Multi-omics: the large-scale analysis of proteins, metabolites, and lipids, powered by advanced mass spectrometry and AI, offering a fuller picture of human health.
In this episode, David Brühlmann meets Mo Jain, founder and CSO of Sapient, a leader in multi-omics analytics. With over two decades of experience across physiology, biomedicine, and computational biology, Mo has been at the forefront of developing scalable multi-omics technologies that are changing the way we predict, diagnose, and treat disease. From leading an academic lab to building a pioneering biotech company, Mo’s journey reflects a passion for uncovering the hidden 80–90% of disease risk that lies beyond our genes.
Here are three reasons you’ll want to listen to this episode:
Ready to think beyond your genes? The biotech revolution is here, and it starts in your neighborhood.
Connect with Mo Jain:
LinkedIn: www.linkedin.com/in/mo-jain-md-phd-373895ba
Website: www.sapient.bio
Company LinkedIn Page: https://www.linkedin.com/company/sapientbio
Next step:
Book a free consultation to help you get started on any questions you may have about bioprocessing analytics: https://bruehlmann-consulting.com/call
Develop bioprocessing technologies better, faster, at a fraction of the cost with our 1:1 Strategy Call: The quickest and easiest way to excel biotech technology development. Book your call at https://stan.store/SmartBiotech
En liten tjänst av I'm With Friends. Finns även på engelska.